Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations

, MT Newswires - 2:20 PM ET 4/14/2025 default

02:20 PM EDT, 04/14/2025 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Monday it expects to generate $685 million in projected future revenues from its collaborations.

The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.

The company said it also expects "substantial" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.

Can-Fite BioPharma ( CANF ) shares were up 1.58% in recent trading Monday before the trading was halted pending material news.

Price: 1.60, Change: +0.02, Percent Change: +1.59

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.